<DOC>
	<DOCNO>NCT02594124</DOCNO>
	<brief_summary>The primary objective evaluate long-term safety tolerability nusinersen ( ISIS 396443 ) administer intrathecal ( IT ) injection participant Spinal Muscular Atrophy ( SMA ) previously participate investigational study nusinersen . The secondary objective examine long-term efficacy nusinersen administer IT injection participant SMA previously participate investigational study nusinersen .</brief_summary>
	<brief_title>A Study Participants With Spinal Muscular Atrophy ( SMA ) Who Previously Participated Nusinersen ( ISIS 396443 ) Investigational Studies .</brief_title>
	<detailed_description>This study initiate protocol register Ionis Pharmaceuticals , Inc . In August 2016 , Biogen assume responsibility study .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Signed informed consent parent guardian sign informed assent participant , indicate per participant 's age institutional guideline . Completion index study accordance study protocol result Sponsor decision ( e.g. , early termination index study ) within precede 16 week Key Have condition worsen condition opinion Investigator would make participant unsuitable enrollment , could interfere participant participate complete study Clinically significant abnormality hematology clinical chemistry parameter electrocardiogram ( ECG ) , assess Site Investigator , Screening visit would render participant unsuitable participation study Participant 's parent legal guardian willing able meet standard care guideline ( include vaccination respiratory syncytial virus prophylaxis available ) , provide nutritional respiratory support throughout study Treatment another investigational agent , biological agent , device within one month Screening , 5 halflives study agent , whichever long NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>SMN</keyword>
	<keyword>SMNRx</keyword>
	<keyword>ISIS-SMNRx</keyword>
	<keyword>ISIS-SMN Rx</keyword>
	<keyword>ISIS 396443</keyword>
	<keyword>SHINE</keyword>
	<keyword>IONIS-SMNRx</keyword>
	<keyword>IONIS-SMN Rx</keyword>
	<keyword>Spinraza</keyword>
	<keyword>nusinersen</keyword>
</DOC>